$VVOS
Vivos Therapeutics, Inc. Stock $vvos

$vvos Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223029161 Filed on August 16, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$3.301M	$3.395M	$4.184M
YoY Change	-22.26%	-18.86%	-6.96%
Cost Of Revenue	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	-88.54%
Gross Profit	$1.898M	$2.098M	$2.588M
YoY Change	-23.96%	-18.93%	-28.59%
Gross Profit Margin	57.5%	61.8%	61.85%
Selling, General & Admin	$5.237M	$6.467M	$9.390M
YoY Change	-32.23%	-31.13%	25.36%
% of Gross Profit	275.92%	308.25%	362.83%
Research & Development	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	0.0%
% of Gross Profit	5.27%	4.77%	3.86%
Depreciation & Amortization	$200.0K	$148.0K	$200.0K
YoY Change	0.0%	-26.0%	4.02%
% of Gross Profit	10.54%	7.05%	7.73%
Operating Expenses	$5.387M	$6.615M	$9.552M
YoY Change	-31.84%	-30.75%	24.29%
Operating Profit	-$3.489M	-$4.517M	-$6.964M
YoY Change	-35.47%	-35.14%	71.47%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$53.00K	-$225.0K	-$28.00K
YoY Change	96.3%	703.57%
Pretax Income	-$2.090M	-$5.528M	-$6.992M
YoY Change	-61.54%	-20.94%	72.96%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$2.093M	-$5.528M	-$6.992M
YoY Change	-61.48%	-20.94%	72.96%
Net Earnings / Revenue	-63.41%	-162.83%	-167.11%
Basic Earnings Per Share	-$1.75	-$0.18	-$0.33
Diluted Earnings Per Share	-$1.75	-$0.18	-$329.3K
COMMON SHARES
Basic Shares Outstanding	29.93M shares	29.93M shares	21.23B shares
Diluted Shares Outstanding	1.197M shares	29.93M shares	21.23M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$990.0K	$3.942M	$12.66M
YoY Change	-85.27%	-68.87%	-62.98%
Cash & Equivalents	$1.000M	$3.900M	$12.70M
Short-Term Investments
Other Short-Term Assets	$770.0K	$1.073M	$2.061M
YoY Change	-63.61%	-47.94%	23.2%
Inventory
Prepaid Expenses
Receivables	$228.0K	$327.0K	$791.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.985M	$5.342M	$15.51M
YoY Change	-79.54%	-65.56%	-60.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.283M	$3.267M	$3.109M
YoY Change	7.85%	5.08%	35.7%
Goodwill	$2.843M	$2.843M	$2.843M
YoY Change	0.0%	0.0%
Intangibles	$433.0K	$445.0K	$322.0K
YoY Change	38.78%	38.2%
Long-Term Investments
YoY Change
Other Assets	$310.0K	$308.0K	$373.0K
YoY Change	-16.67%	-17.43%	-0.44%
Total Long-Term Assets	$8.332M	$8.407M	$8.862M
YoY Change	-4.22%	-5.13%	30.95%
TOTAL ASSETS
Total Short-Term Assets	$1.985M	$5.342M	$15.51M
Total Long-Term Assets	$8.332M	$8.407M	$8.862M
Total Assets	$10.32M	$13.75M	$24.38M
YoY Change	-43.93%	-43.59%	-47.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.528M	$1.325M	$1.252M
YoY Change	137.27%	5.83%	-3.6%
Accrued Expenses	$1.922M	$1.949M	$2.618M
YoY Change	-11.79%	-25.55%	-0.68%
Deferred Revenue	$2.373M	$2.359M	$2.080M
YoY Change	-1.17%	13.41%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.167M	$8.440M	$6.694M
YoY Change	20.17%	26.08%	-28.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.100M	$3.203M	$2.842M
YoY Change	20.11%	12.7%	692.97%
Total Long-Term Liabilities	$3.100M	$3.203M	$2.842M
YoY Change	20.11%	12.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.167M	$8.440M	$6.694M
Total Long-Term Liabilities	$3.100M	$3.203M	$2.842M
Total Liabilities	$10.30M	$11.60M	$9.500M
YoY Change	21.18%	22.11%	-1.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$88.80M	-$86.70M	-$67.90M
YoY Change	20.98%	27.69%
Common Stock	$3.000K	$3.000K	$2.000K
YoY Change	50.0%	50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$46.00K	$2.106M	$14.84M
YoY Change
Total Liabilities & Shareholders Equity	$10.32M	$13.75M	$24.38M
YoY Change	-43.93%	-43.59%	-47.19%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$2.093M	-$5.528M	-$6.992M
YoY Change	-61.48%	-20.94%	72.96%
Depreciation, Depletion And Amortization	$200.0K	$148.0K	$200.0K
YoY Change	0.0%	-26.0%	4.02%
Cash From Operating Activities	-$2.800M	-$2.859M	-$4.663M
YoY Change	-52.07%	-38.69%	26.21%
INVESTING ACTIVITIES
Capital Expenditures	$160.0K	$245.0K	-$504.0K
YoY Change	-260.0%	-148.61%	-61.61%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$160.0K	-$245.0K	-$504.0K
YoY Change	60.0%	-51.39%	-67.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-2.800M	-2.859M	-4.663M
Cash From Investing Activities	-160.0K	-245.0K	-504.0K
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	-2.960M	-3.104M	-5.167M
YoY Change	-50.19%	-39.93%	-125.65%
FREE CASH FLOW
Cash From Operating Activities	-$2.800M	-$2.859M	-$4.663M
Capital Expenditures	$160.0K	$245.0K	-$504.0K
Free Cash Flow	-$2.960M	-$3.104M	-$4.159M
YoY Change	-48.45%	-25.37%	74.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	VVOS	Gain Loss On Ppp Loan Forgiveness GainLossOnPPPLoanForgiveness		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001716166
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	VVOS	Warrant Liability WarrantLiability		usd
CY2022Q4	VVOS	Employee Retention Credit Liability EmployeeRetentionCreditLiability		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q2	VVOS	Excess Warrant Fair Value ExcessWarrantFairValue		usd
	VVOS	Excess Warrant Fair Value ExcessWarrantFairValue		usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	VVOS	Excess Warrant Fair Value ExcessWarrantFairValue		usd
	VVOS	Forgiveness Of Indebtedness Income ForgivenessOfIndebtednessIncome		usd
	VVOS	Increase Decrease In Improvement Allowances IncreaseDecreaseInImprovementAllowances		usd
	VVOS	Employees Retention Credit Liability EmployeesRetentionCreditLiability		usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets		usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	VVOS	Fair Value Of Prefunded Warrants Exercised FairValueOfPrefundedWarrantsExercised		usd
	VVOS	Fair Value Of Prefunded Warrants Exercised FairValueOfPrefundedWarrantsExercised		usd
	VVOS	Fair Value Of Common Stock Issued In Asset Purchase FairValueOfCommonStockIssuedInAssetPurchase		usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39796
	dei	Entity Registrant Name EntityRegistrantName	Vivos Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3224056
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7921 Southpark Plaza
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
	dei	Entity Address City Or Town EntityAddressCityOrTown	Littleton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80120
	dei	City Area Code CityAreaCode	(866)
	dei	Local Phone Number LocalPhoneNumber	908-4867
	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	VVOS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29928786	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3942000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3519000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	251000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	712000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	327000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	457000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1073000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1448000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	5342000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	5424000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	2843000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2843000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3267000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3082000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1544000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1695000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	445000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	302000	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	308000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	374000	usd
CY2023Q2	us-gaap	Assets Assets	13749000	usd
CY2022Q4	us-gaap	Assets Assets	13720000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1325000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1411000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1949000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1912000	usd
CY2023Q2	VVOS	Warrant Liability WarrantLiability	2200000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2359000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2926000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	447000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	419000	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	160000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	145000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8440000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6813000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	264000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	112000	usd
CY2023Q2	VVOS	Employee Retention Credit Liability EmployeeRetentionCreditLiability	1175000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1764000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1994000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	11643000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8919000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29928786	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29928786	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23012119	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23012119	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88802000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	84267000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86699000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79468000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2106000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4801000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13749000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13720000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3395000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4184000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7253000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7828000	usd
CY2023Q2	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	1297000	usd
CY2022Q2	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	1596000	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	2817000	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	2689000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	2098000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	2588000	usd
	us-gaap	Gross Profit GrossProfit	4436000	usd
	us-gaap	Gross Profit GrossProfit	5139000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5877000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7691000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12414000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15497000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	590000	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1699000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1220000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2879000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	148000	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	162000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	323000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	324000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	6615000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	9552000	usd
	us-gaap	Operating Expenses OperatingExpenses	13957000	usd
	us-gaap	Operating Expenses OperatingExpenses	18700000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4517000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6964000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9521000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13561000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-225000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-37000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-174000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-116000	usd
	VVOS	Gain Loss On Ppp Loan Forgiveness GainLossOnPPPLoanForgiveness	-1287000	usd
	VVOS	Excess Warrant Fair Value ExcessWarrantFairValue	6453000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	645000	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	867000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-8761000	usd
CY2023Q2	VVOS	Other Income Non Operating OtherIncomeNonOperating	81000	usd
CY2022Q2	VVOS	Other Income Non Operating OtherIncomeNonOperating	9000	usd
	VVOS	Other Income Non Operating OtherIncomeNonOperating	156000	usd
	VVOS	Other Income Non Operating OtherIncomeNonOperating	68000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5528000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-6992000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7231000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12322000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29928786	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29928786	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21233485	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21233485	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28245084	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28245084	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21233485	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21233485	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29928786	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21233485	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28245084	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21233485	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	25539000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	222000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	609000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5331000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	21039000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	131000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	661000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-6992000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	14839000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4801000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	116000	usd
CY2023Q1	VVOS	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	2848000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	625000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	306000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1703000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6993000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6993000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	182000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	459000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5528000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2106000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2106000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7231000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12322000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	765000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1271000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	323000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	324000	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-36000	usd
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	808000	usd
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	352000	usd
	us-gaap	Payments Of Derivative Issuance Costs PaymentsOfDerivativeIssuanceCosts	645000	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	8761000	usd
	VVOS	Excess Warrant Fair Value ExcessWarrantFairValue	6453000	usd
	VVOS	Forgiveness Of Indebtedness Income ForgivenessOfIndebtednessIncome	1265000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-130000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-411000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-52000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-19000	usd
	VVOS	Increase Decrease In Improvement Allowances IncreaseDecreaseInImprovementAllowances	516000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-375000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	486000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-79000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	16000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-86000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	331000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	37000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-106000	usd
	VVOS	Employees Retention Credit Liability EmployeesRetentionCreditLiability	1175000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	230000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-415000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6398000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10745000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	484000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	624000	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	50000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-534000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-624000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	8000000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	645000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7355000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	423000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11369000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3519000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24030000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3942000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12661000	usd
	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
	VVOS	Fair Value Of Common Stock Issued In Asset Purchase FairValueOfCommonStockIssuedInAssetPurchase	116000	usd
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	VVOS	Percentage Of Revenue PercentageOfRevenue	0.80	pure
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_z67xOC22gKgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zZAd8mzxyaSi">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires the Company to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. The Company bases its estimates and assumptions on existing facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, assessing collectability on accounts receivable, the determination of customer life and breakage related to recognizing revenue for VIP contracts, impairment of goodwill and long-lived assets; valuation assumptions for assets acquired in asset acquisitions; valuation assumptions for stock options, warrants, warrant liabilities and equity instruments issued for goods or services; deferred income taxes and the related valuation allowances; and the evaluation and measurement of contingencies. Additionally, the full impact of COVID-19 is unknown and cannot be reasonably estimated. However, the Company has made appropriate accounting estimates based on the facts and circumstances available as of the reporting date. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	VVOS	Gross Receipt Percentage GrossReceiptPercentage	0.50	pure
	VVOS	Employee Retain Description EmployeeRetainDescription	Healthcare plan expenses were not included in the analysis, although they are eligible if an employee has paid health insurance through their paycheck. Section 2301(c)(5)(B) of the CARES Act provides that “wages” include amounts paid by an eligible employer to provide and maintain a group health plan (as defined in section 5000(b)(1) of the Code), but only to the extent that the amounts are excluded from the gross income of employees by reason of section 106(a) of the Code. The Company pays the first $500 of healthcare insurance for each employee, which generally covers the monthly cost of their insurance. Because of this, the Company conservatively did not include any of the cost of insurance in its analysis. Additionally, PPP loan amounts were deducted from the amount of total wages paid before calculating the qualified ERTC wages. The Company applied for the ERTC using Vivos Therapeutics Inc.’s payroll which covers 95% of its employees
	VVOS	Eligible Tax Credit Description EligibleTaxCreditDescription	As indicated above, for 2020, companies were eligible for a credit equal to 50 percent of the first ten thousands of qualified wages paid per employee in the aggregate of each eligible quarter. Therefore, the maximum ERTC for the Company for 2020 is five thousand ($5,000) per employee. For the second and fourth quarters of 2020, the total eligible credit was limited to approximately $0.5 million
CY2023Q2	VVOS	Credit Percentage CreditPercentage	0.70	pure
CY2023Q2	VVOS	Credit Limit CreditLimit	700000	usd
CY2023Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1200000	usd
CY2022Q2	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	1556000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1068000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1320000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	200000	usd
	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2623000	usd
	VVOS	Warrant Accounting Policy Textblock WarrantAccountingPolicyTextblock	<p id="xdx_843_ecustom--WarrantAccountingPolicyTextblock_z4D4dYmbqfyg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zU60D3CzFlq7">Warrant Accounting</span> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its warrants and financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with <i>ASC 815, Derivatives and Hedging</i>. Warrants classified as equity are recorded at fair value as of the date of issuance on the Company’s consolidated balance sheets and no further adjustments to their valuation are made. Warrants classified as liabilities and other financial instruments that require separate accounting as liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and will be revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using the Black-Scholes model and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Net Income Loss NetIncomeLoss	-7200000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12300000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86700000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6400000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10700000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	11600000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3900000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3395000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4184000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7253000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7828000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3038000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2399000	usd
CY2023Q1	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	1255000	usd
CY2022Q1	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	1183000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1396000	usd
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1421000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2897000	usd
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2161000	usd
CY2023Q2	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	794000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2397000	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2400000	usd
CY2023Q2	VVOS	Revenue From Breakage On Contract Liabilities RevenueFromBreakageOnContractLiabilities	100000	usd
CY2022Q2	VVOS	Revenue From Breakage On Contract Liabilities RevenueFromBreakageOnContractLiabilities	100000	usd
	VVOS	Revenue From Breakage On Contract Liabilities RevenueFromBreakageOnContractLiabilities	200000	usd
	VVOS	Revenue From Breakage On Contract Liabilities RevenueFromBreakageOnContractLiabilities	200000	usd
CY2023Q2	us-gaap	Receivables From Customers ReceivablesFromCustomers	300000	usd
CY2022Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	500000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	300000	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5320000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4835000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2053000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1753000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3267000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3082000	usd
CY2023Q2	us-gaap	Area Of Land AreaOfLand	15000	sqft
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	2800000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2800000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	2843000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2843000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2659000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2493000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2214000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2191000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	445000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	302000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	25000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	50000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	50000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	35000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	29000	usd
CY2023Q2	VVOS	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	256000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	445000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.61
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	100000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.41
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1346000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1358000	usd
CY2023Q2	VVOS	Accrued Legal And Other AccruedLegalAndOther	556000	usd
CY2022Q4	VVOS	Accrued Legal And Other AccruedLegalAndOther	473000	usd
CY2023Q2	VVOS	Accrued Lab Rebate Liabilities Current AccruedLabRebateLiabilitiesCurrent	47000	usd
CY2022Q4	VVOS	Accrued Lab Rebate Liabilities Current AccruedLabRebateLiabilitiesCurrent	81000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1949000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1912000	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	250000	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	50000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	200000	usd
CY2023Q1	us-gaap	Cash Cash	200000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	400000	shares
CY2023Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2023Q2	VVOS	Vested Warrants VestedWarrants	250000	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	114000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	135000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	243000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	262000	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	114000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	135000	usd
	us-gaap	Lease Cost LeaseCost	243000	usd
	us-gaap	Lease Cost LeaseCost	262000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.083	pure
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21233485	shares
	VVOS	Schedule Of Cash Flow Information Related To Leases ScheduleOfCashFlowInformationRelatedToLeases	<p id="xdx_89E_ecustom--ScheduleOfCashFlowInformationRelatedToLeases_zMmHcsz06PV9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to leases as of June 30, 2023 is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <span id="xdx_8B6_zMidUUr3961a" style="display: none">SCHEDULE OF RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20230101__20230630_z5ra8VV6cjM2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flow classification of lease payments:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_ecustom--OperatingCashFlowsFromOperatingLeases_pn3n3_zAsff7iWYDOl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating cash flows from operating leases</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">299</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table>
	VVOS	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	299000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	304000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	621000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	594000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	507000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	493000	usd
CY2023Q2	VVOS	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	140000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2659000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	448000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2211000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5528000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-6992000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7231000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12322000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5528000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6992000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7231000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12322000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29928786	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29928786	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21233485	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21233485	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28245084	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28245084	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21233485	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21233485	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29928786	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28245084	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21233485	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15847	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7235	shares
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	14453000	usd
CY2023Q1	VVOS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Exercise FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercise	2847000	usd
CY2023Q1	VVOS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value Upon Remeasurement FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValueUponRemeasurement	10273000	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1333000	usd
CY2023Q2	VVOS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value Upon Remeasurement FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValueUponRemeasurement	-867000	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2200000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3900000	usd

Files In Submission

Name	View Source	Status
0001493152-23-029161-index-headers.html	Edgar Link	pending
0001493152-23-029161-index.html	Edgar Link	pending
0001493152-23-029161.txt	Edgar Link	pending
0001493152-23-029161-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vvos-20230630.xsd	Edgar Link	pending
vvos-20230630_cal.xml	Edgar Link	unprocessable
vvos-20230630_def.xml	Edgar Link	unprocessable
vvos-20230630_pre.xml	Edgar Link	unprocessable
vvos-20230630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VVOS
Vivos Therapeutics, Inc. Stock $vvos

2023 Q3 Form 10-Q Financial Statement

#000149315223029161 Filed on August 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VVOS Vivos Therapeutics, Inc. Stock $vvos

2023 Q3 Form 10-Q Financial Statement

#000149315223029161 Filed on August 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VVOS
Vivos Therapeutics, Inc. Stock $vvos